

# Novel therapeutics and personalised diagnostics



Friday 24<sup>th</sup> June 2016 9.30am to 5.30pm Royal Armouries Leeds

<b>Welcome (9.20am - 9.30am)</b>	<b>Cathy Burton</b>	<b>HMDS, Leeds</b>
<b>Session 1</b>		
<b>Chair: TBC</b>	<b>Myeloid malignancies (9.30 am to 10.45 am)</b>	
Novel therapies in AML	David Bowen	Leeds Teaching Hospitals
Targeted therapies in myeloproliferative neoplasms	Mary Frances McMullin	Queens University, Belfast
Novel approaches to diagnosis of MDS	Matt Cullen	HMDS, Leeds
<b>COFFEE 10.45-11.15</b>		
<b>Session 2</b>		
<b>Chair: John Ashcroft</b>	<b>Plasma cell session (11.15-12.00)</b>	
Myeloma	Graham Jackson	Newcastle Hospitals NHS Foundation Trust
Diagnostics in plasma cell neoplasms	Ruth de Tute	HMDS, Leeds
<b>Session 3</b>		
<b>Chair: TBC</b>	<b>CLL session (12.00-12.45pm)</b>	
Title to be confirmed	George Follows	Cambridge Uni Hospitals NHS Foundation Trust
Diagnostic criteria of CLL	Andy Rawstron	HMDS, Leeds
<b>LUNCH 12.45- 1.40</b>		
<b>Session 3</b>		
<b>Chair: Andrew Jack</b>	<b>Genomics session (1.40- 2.50pm)</b>	
The future of genomics	Sue Hill	NHS England
Title to be confirmed	Mike Messenger	Leeds University
Constitutional genetic disorders in haem malignancy	Ruth Charlton	Leeds Genetics Laboratory
<b>Session 4</b>		
<b>Chair:</b>	<b>Lymphoma session (2.50-3.50pm)</b>	
DLBCL	Andy Davies	University of Southampton
Title to be confirmed	Rebecca Auer	Barts Health NHS Trust
<b>COFFEE 3.50 – 4.20</b>		
<b>Session 5</b>		
<b>Chair: Roger Owen</b>	<b>Case studies (4.20pm-5.20pm)</b>	
<b>Close meeting (5.20-5.30pm)</b>	Cathy Burton	HMDS, Leeds